In vitro CYP3A4 Metabolism: Inhibition by Echinacea purpurea and Choice of Substrate for the Evaluation of Herbal Inhibition

被引:21
|
作者
Hansen, Torstein Schroder [1 ]
Nilsen, Odd Georg [1 ]
机构
[1] Norwegian Univ Sci & Technol, Fac Med, Dept Canc Res & Mol Med, Med Tech Res Ctr, N-7489 Trondheim, Norway
关键词
D O I
10.1111/j.1742-7843.2008.00307.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The in vitro CYP3A4 inhibition profiles of Echinacea purpurea, St. John's wort and ketoconazole were evaluated by three different substrates: 7-benzyloxy-trifluoromethylcoumarin (BFC), 7-benzyloxyquinoline (BQ) and testosterone. St. John's wort and ketoconazole produced similar inhibition profiles regardless of substrate. For E. purpurea, testosterone metabolism showed a much lower CYP3A4 inhibition (IC50 5394 mu g/ml) compared to the fluorescent substrates BFC and BQ (IC50 354 and 452 mg/ml, respectively). It is suggested that the substrate/assay-dependent effects may arise from a complex nature of E. purpurea constituents, involving different CYP3A4 substrate binding sites. The choice of substrate might thus be essential for evaluation of the inhibition of CYP3A4 metabolism for some herbs. A weak inhibition potential of E. purpurea towards CYP3A4-mediated metabolism in vitro was confirmed by the use of three different substrates.
引用
收藏
页码:445 / 449
页数:5
相关论文
共 50 条
  • [21] Potent in vitro Inhibition of CYP3A4 and P-Glycoprotein by Rhodiola rosea
    Hellum, Bent H.
    Tosse, Anita
    Hoybakk, Kathrine
    Thomsen, Mette
    Rohloff, Jens
    Nilsen, Odd Georg
    PLANTA MEDICA, 2010, 76 (04) : 331 - 338
  • [22] Inhibition of the metabolism of brotizolam by erythromycin in humans:: in vivo evidence for the involvement of CYP3A4 in brotizolam metabolism
    Tokairin, T
    Fukasawa, T
    Yasui-Furukori, N
    Aoshima, T
    Suzuki, A
    Inoue, Y
    Tateishi, T
    Otani, K
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 60 (02) : 172 - 175
  • [23] Interaction involving tadalafil and CYP3A4 inhibition by ritonavir
    Loulergue, Pierre
    Gaillard, Raphael
    Mir, Olivier
    SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2011, 43 (03) : 239 - U1
  • [24] Contribution of metabolites to in vivo CYP3A4 inhibition by itraconazole
    Templeton, Ian E.
    Thummel, Kenneth E.
    Isoherranen, Nina
    Kharasch, Evan David
    Kunze, Kent L.
    Nelson, Wendel L.
    Hoffer, Christine
    DRUG METABOLISM REVIEWS, 2006, 38 : 127 - 128
  • [25] Mechanism-based inhibition of CYP3A4 by zafirlukast
    Lanza, DL
    Skordos, KW
    Borges, CR
    Yost, GS
    DRUG METABOLISM REVIEWS, 2004, 36 : 285 - 285
  • [26] Differential inhibition of CYP3A4 and CYP3A5 by verapamil.
    Wang, Y
    Jones, DR
    Hall, SD
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P16 - P16
  • [27] Genetic variations of CYP3A4 on the metabolism of itraconazole in vitro
    Xie, Sai-li
    Zhu, Xiayan
    Gao, Nanyong
    Lin, Qianmeng
    Chen, Chaojie
    Yang, Yun-jun
    Cai, Jian-ping
    Hu, Guo-xin
    Xu, Ren-ai
    FOOD AND CHEMICAL TOXICOLOGY, 2023, 181
  • [28] Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo
    Templeton, I. E.
    Thummel, K. E.
    Kharasch, E. D.
    Kunze, K. L.
    Hoffer, C.
    Nelson, Wl
    Isoherranen, N.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (01) : 77 - 85
  • [29] Effects of CYP3A4 Variants on Methadone Metabolism In Vitro
    Wang, Chen-chen
    Zhang, Ming-lei
    Xu, Yan-dan
    Hu, Guo-xin
    Cai, Jian-ping
    Lan, Tian
    Bai, Yong-feng
    BIOMEDICAL CHROMATOGRAPHY, 2025, 39 (01)
  • [30] In vitro metabolism of piperaquine is primarily mediated by CYP3A4
    Lee, Tina Ming-Na
    Huang, Liusheng
    Johnson, Marla K.
    Lizak, Patricia
    Kroetz, Deanna
    Aweeka, Francesca
    Parikh, Sunil
    XENOBIOTICA, 2012, 42 (11) : 1088 - 1095